RecruitingPhase 1NCT07401472
Study of BW-50218 in Healthy Participants
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-50218 in Healthy Participants
Sponsor
Shanghai Argo Biopharmaceutical Co., Ltd.
Enrollment
60 participants
Start Date
Feb 25, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria4
- Capable of providing written informed consent and complying with all study procedures for the duration of the study.
- Body weight and body mass index (BMI) within a range considered appropriate for study participation by the investigator.
- Female participants must be non-pregnant, non-lactating, and either of non-childbearing potential or using highly effective contraception.
- Male participants with partners of childbearing potential must agree to use effective contraception.
Exclusion Criteria5
- Any medical condition, recent illness, or laboratory result that, in the investigator's opinion, may increase risk or interfere with participation in the study.
- Recent hospitalization or a significant acute medical event.
- History of cancer or any long-term medical condition that the study doctor considers clinically relevant.
- Clinical laboratory findings outside of range which are deemed clinically significant by the investigator at screening or Day -1.
- Positive test for hepatitis B, hepatitis C, or HIV.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBW-50218 Injection
Solution for injection
DRUGSaline (0.9% NaCl)
Solution for injection
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07401472